Alto Neuroscience (stock code: ANRO) has successfully completed patient enrollment for its Phase II proof-of-concept study of the candidate drug Alto-101 for cognitive impairment associated with schizophrenia.

Alto Neuroscience (stock code: ANRO) has successfully completed patient enrollment for its Phase II proof-of-concept study of the candidate drug Alto-101 for cognitive impairment associated with schizophrenia.

老虎证券2026/02/13 13:28

Show original

The completion of this study marks an important milestone in the clinical development process of the drug, laying a foundation for subsequent evaluation of its efficacy and safety.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

Alto Neuroscience (stock code: ANRO) has successfully completed patient enrollment for its Phase II proof-of-concept study of the candidate drug Alto-101 for cognitive impairment associated with schizophrenia.

You may also like

Trending news

Crypto prices